ATE412763T1 - Antikörper-abhängige vergrösserung der alphavirus-infektvität - Google Patents

Antikörper-abhängige vergrösserung der alphavirus-infektvität

Info

Publication number
ATE412763T1
ATE412763T1 AT00963282T AT00963282T ATE412763T1 AT E412763 T1 ATE412763 T1 AT E412763T1 AT 00963282 T AT00963282 T AT 00963282T AT 00963282 T AT00963282 T AT 00963282T AT E412763 T1 ATE412763 T1 AT E412763T1
Authority
AT
Austria
Prior art keywords
cell
alphavirus
subject
preferred
infectivity
Prior art date
Application number
AT00963282T
Other languages
English (en)
Inventor
Gene Macdonald
Robert Johnston
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE412763T1 publication Critical patent/ATE412763T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00963282T 1999-08-31 2000-08-30 Antikörper-abhängige vergrösserung der alphavirus-infektvität ATE412763T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15171899P 1999-08-31 1999-08-31
US17743500P 2000-01-21 2000-01-21

Publications (1)

Publication Number Publication Date
ATE412763T1 true ATE412763T1 (de) 2008-11-15

Family

ID=26848900

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00963282T ATE412763T1 (de) 1999-08-31 2000-08-30 Antikörper-abhängige vergrösserung der alphavirus-infektvität

Country Status (8)

Country Link
US (1) US7651998B1 (de)
EP (1) EP1208217B1 (de)
JP (1) JP2003508056A (de)
AT (1) ATE412763T1 (de)
AU (1) AU782645B2 (de)
CA (1) CA2383519A1 (de)
DE (1) DE60040672D1 (de)
WO (1) WO2001016343A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
EP1608762B1 (de) 2003-03-20 2014-01-08 Alphavax, Inc. Verbesserte alphavirus replikons und helferkonstrukt
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
EP1856250B1 (de) 2005-02-15 2013-07-24 The University of North Carolina At Chapel Hill Neue lebende virus-impfstoffe
WO2008147847A1 (en) * 2007-05-22 2008-12-04 Baylor College Of Medicine Immune complex vaccination as a strategy to enhance immunity in the elderly and other immune compromised populations
DK2947149T3 (en) 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
US20120107355A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004807A (en) 1992-03-30 1999-12-21 Schering Corporation In vitro generation of human dendritic cells
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0659885A1 (de) 1993-12-21 1995-06-28 Akzo Nobel N.V. Impstoffe gegen von Antikörper abhängende Vergrösserung (ADE) der Virus-Infektivität
US5505947A (en) * 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU749345B2 (en) * 1997-11-14 2002-06-27 Connaught Laboratories Limited Alphavirus vectors for paramyxovirus vaccines
US20010041876A1 (en) 1999-12-23 2001-11-15 Creagan Christopher Cosgrove Superabsorbent and nonwoven composites for personal care products

Also Published As

Publication number Publication date
EP1208217A1 (de) 2002-05-29
WO2001016343A1 (en) 2001-03-08
EP1208217B1 (de) 2008-10-29
DE60040672D1 (de) 2008-12-11
JP2003508056A (ja) 2003-03-04
AU782645B2 (en) 2005-08-18
US7651998B1 (en) 2010-01-26
CA2383519A1 (en) 2001-03-08
AU7471800A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
Zom et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates
Bao et al. Chimeric exosomes functionalized with STING activation for personalized glioblastoma immunotherapy
Daftarian et al. Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells
GB2431582A (en) Dendritic cell vaccines for treating cancer made from embryonic stem cells
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
DK1633784T3 (da) OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder
NO20021992D0 (no) Anti-prostatastamcelleantigen(PSCA)-antistoffpreparat og fremgangsmåter for anvendelse
ATE432085T1 (de) Stimulationsfaktor für dendriten
Anticoli et al. Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells
DE60040672D1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
WO2005046573A3 (en) Pro104 antibody compositions and methods of use
ATE309378T1 (de) Abgeschwächter salmonellenstamm, gebraucht als vehikel zur oralen immunisierung
ATE389712T1 (de) Krebs immuntherapie mit semi-allogenen zellen
WO2002036790A3 (en) Influenza virus vector for infection of dendritic cells
Li et al. Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B/CD 4 T cell crosstalk
Aspord et al. pDCs efficiently process synthetic long peptides to induce functional virus‐and tumour‐specific T‐cell responses
Chen et al. Manganese‐CpG Nanocomposite Integrates ROS‐Induced Cell Apoptosis and STING‐Activated and Adjuvant‐Augmented Immune Responses for Tumor Elimination and Prevention
GB2355983A (en) Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class 1 molecule and an attaching means
DE50008756D1 (de) Peptid aus antigen muc-1 zur auslösung einer immunreaktion gegen tumorzellen
ATE374244T1 (de) Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden
AU4935600A (en) New vaccine formulations - 2
DK1444261T3 (da) Immunogene ALK (anaplastisk lymfomakinase) peptider
Gao et al. PD‐L1‐Binding Antigen Presenters: Redirecting Vaccine‐Induced Antibodies for Cancer Immunotherapy
WO2001026680A3 (en) Activation of antigen-specific t cells by virus/antigen-treated dendritic cells
AU2014250632B2 (en) Products and methods for stimulating an immune response

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties